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Abstract: Hydroxytyrosol (HT) is a natural phenolic antioxidant which has neuroprotective effects
in models of Parkinson’s disease (PD). Due to issues such as rapid metabolism, HT is unlikely
to reach the brain at therapeutic concentrations required for a clinical effect. We have previously
developed micellar nanocarriers from Pluronic F68® (P68) and dequalinium (DQA) which have
suitable characteristics for brain delivery of antioxidants and iron chelators. The aim of this study
was to utilise the P68 + DQA nanocarriers for HT alone, or in combination with the iron chelator
deferoxamine (DFO), and assess their physical characteristics and ability to pass the blood–brain
barrier and protect against rotenone in a cellular hCMEC/D3-SH-SY5Y co-culture system. Both HT
and HT + DFO formulations were less than 170 nm in size and demonstrated high encapsulation
efficiencies (up to 97%). P68 + DQA nanoformulation enhanced the mean blood–brain barrier (BBB)
passage of HT by 50% (p < 0.0001, n = 6). This resulted in increased protection against rotenone
induced cytotoxicity and oxidative stress by up to 12% and 9%, respectively, compared to the
corresponding free drug treatments (p < 0.01, n = 6). This study demonstrates for the first time the
incorporation of HT and HT + DFO into P68 + DQA nanocarriers and successful delivery of these
nanocarriers across a BBB model to protect against PD-related oxidative stress. These nanocarriers
warrant further investigation to evaluate whether this enhanced neuroprotection is exhibited in
in vivo PD models.
Keywords: hydroxytyrosol; deferoxamine; Parkinson’s disease; oxidative stress; antioxidant; neu-
rodegeneration; blood–brain barrier; Transwell®; Pluronic® F68; dequalinium; micelles
1. Introduction
Hydroxytyrosol (HT) is a natural phenolic compound that has generated interest
in Parkinson’s disease (PD) research due to its antioxidant properties. HT is a major
component of olive oil and therefore prominent in the Mediterranean diet [1,2], which
has been related to lower mortality [3,4], improved cardiovascular health [5,6] and slower
cognitive decline [7]. A wide body of research supports a protective role of HT against
neurodegeneration [8–13].
HT’s catecholic structure provides reactive oxygen species (ROS) scavenging prop-
erties through the ability of the benzene ring-bound hydroxyl groups to donate either an
electron or hydrogen atom to stabilise ROS [14–16].
In PD-related cellular models, HT protects dopaminergic neurons against cell death
following oxidative stress [8,11] and protects against alpha synuclein fibril formation and
aggregation in the PC12 cell line [17]. Animal studies have shown resistance to oxidative
stress via reduced lipid peroxidation in dissociated brain cells following administration of
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100 mg/kg HT for 12 days [18], suggesting that HT can access the brain. Although other
studies have also shown that HT can cross the blood–brain barrier (BBB), brain uptake
of HT is lower than uptake in other organs and only reaches the brain in micromolar
concentrations [11,19]. For example, D’Angelo et al. [19] showed that rat brain tissue
resulted in only 0.31% of the 1.5 mg/kg administered dose, 5 min after intravenous injection.
Additionally, Wu et al. [11] showed the maximum concentration reaching rat brain was
2.1 µg/mL 15 min after an intravenous dose of 100 mg/kg. Furthermore, HT is rapidly
metabolised and is therefore unlikely to reach the brain at therapeutic concentrations
required for a clinical effect [20].
Nanocarriers can enhance the potency, stability, bioavailability, and the passage across
biological membranes of incorporated compounds [21–24]. Pluronic F68 (P68) + dequalin-
ium (DQA) nanocarriers have been successfully used to deliver the antioxidants curcumin
and N-acetylcysteine, alone and in combination with the iron chelator deferoxamine
(DFO), to mitochondria within SH-SY5Y cells to protect against a rotenone model of
PD [24,25]. These nanocarriers exhibit many characteristics that make them suitable for
brain penetrance, for example small particle size (<200 nm) and relatively neutral charge
(<10 mV) [23,26–33]. They also target the mitochondria, the main site of iron-induced
oxidative stress and the associated dopaminergic cell death evident in PD [24,25,34–43].
The combination of antioxidants and iron chelators for the treatment of PD may provide a
promising strategy to limit the degenerative process in PD due to the dual approach of free
radical scavenging and iron chelation to limit detrimental free iron availability. Therefore,
the aim of this study was to utilise the P68 + DQA nanocarriers for HT alone, or in combi-
nation with DFO, and assess their physiochemical characteristics and ability to pass the
BBB and protect against rotenone in a cellular hCMEC/D3-SH-SY5Y co-culture system.
2. Materials and Methods
All chemicals were analytical grade or cell culture grade where applicable (unless
otherwise stated). The SH-SY5Y cell line (CRL-2266) was purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA). The hCMEC/D3 cell line was gifted
from Simon McArthur (Queen Mary University of London, London, UK), previously
purchased from VHBio Ltd. (Gateshead, UK).
Collagen from calf skin, Dulbecco’s phosphate buffered saline (DPBS), EGM-2 MV Mi-
crovascular Endothelial Cell Growth Medium-2 BulletKitTM, fibronectin (bovine plasma),
Hank’s Buffered Saline Solution (HBSS) and HEPES Buffer (1 M) were purchased from
Lonza (Slough, UK). The 100× antibiotic-antimycotic, Dulbecco’s modified Eagle medium
(DMEM) Glutamax®, foetal bovine serum (FBS), L-glutamine, methanol (HPLC grade), Min-
imum Essential Media (MEM) and poloxomer 68 (Pluronic® F68) were supplied by Fisher
Scientific, Loughborough, UK. Dequalinium chloride hydrate (95%), 3-Hydroxytyrosol
(≥98%), rotenone (≥95%), Thiazolyl Blue Tetrazolium Blue (MTT), dimethyl sulfoxide
(DMSO), and 2, 4, 6-tripyridyl-s- triazine and iron(III) Chloride Hexahydrate were pur-
chased from Sigma-Aldrich, Gillingham, UK. The mitochondrial hydroxyl radical detection
assay kit (cat no. ab219931) was purchased from Abcam, Cambridge, UK. Milli-Q water
(water purified through a 0.22 µm membrane filter with a resistivity of 18.2 MΩ) was used
in the preparation of experimental reagents. Millex-MP sterile filters were purchased from
Millipore (Watford, UK). Nunc (Roskilde, Denmark) supplied the culture flasks and all
other plastics were purchased from Corning (Flintshire, UK).
2.1. Preparation of HT and HT + DFO Micellar Nanoformulations
All nanoformulations were prepared using a modified thin-film hydration
method [22,24,25,44]. Briefly, 10 mL of methanol was used to dissolve P68 and DQA
with HT or HT + DFO at certain ratios (Table 1). Using the Hei-VAP Advantage Rotary
Evaporator (Heidolph, Schwabach, Germany), evaporation of the methanol was carried
out in a vacuum (200 rpm, 80 ◦C) to obtain a thin film of drug-loaded nanocarriers. Then,
10 mL of distilled water was then used to hydrate the resultant film. This was mixed
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thoroughly at 80 ◦C for 1–2 min and sonicated for another 1 min using a VWR Ultrasonic
cleaner bath USC300T (VWR International Limited, Lutterworth, UK) to fully dissolve
the film in the water. The obtained solution was filtered through a sterile 0.22 µm filter to
remove any unloaded HT and DFO. Some samples were freeze dried (lyophilized) using
a Virtis AdVantage 2.0 BenchTop freezedryer (SP Industries, Ipswich, UK) for the X-ray
diffraction (XRD) and fourier-transform infrared (FTIR) analyses.
Table 1. Hydrodynamic diameter (d), polydispersity index (PDI), surface charge, drug loading (DL) and encapsulation
efficiency (EE) of blank and drug-loaded P68 + DQA nanoformulations prepared at 80 ◦C (mean ± S.D., n = 6).
Sample Contents (mg/mL) d (nm) PDI Charge (mV) DL (%) EE (%)
P68 + DQA (Blank)
P68: 9










146.26 ± 8.88 0.18 ± 0.07 9.87 ± 1.21
HT: HT:
DQA: 1 1.69 ± 0.03 97.17 ± 1.81
HT: 0.24 DFO: DFO:
DFO: 5 27.26 ± 0.30 76.72 ± 1.42
2.2. Size and Surface Charge of the Nanoformulations
The Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) was used to an-
alyze the dimensions and surface charge of the nanoformulations. Photon correlation
spectroscopy was used to measure size distribution as Z-Ave hydrodynamic diameter and
polydispersity index.
2.3. Determination of Drug Loading and Encapsulation Efficiency
Drug loading and encapsulation efficiency of the nanoformulations was studied
using UV-Visible (UV-Vis) spectroscopy based on the calibration curves of the free drugs.
Methanol and water were used in a 1:1 ratio to dissolve the carrier and release the drug to
achieve a theoretical concentration of 20 µg/mL HT and DFO. HT and DFO content were
calculated using UV-Vis spectroscopy (Cary 100 UV-Vis, Agilent Technologies, Santa Clara,
CA, USA) at 280 and 204 nm, respectively. The following equations were used to calculate
the percentage of drug loading and encapsulation efficiency:
Drug loading (%) = (determined mass of drug within nanocarriers/mass of drug-loaded nanocarriers) × 100 (1)
Encapsulation efficiency (%) = (determined mass of drug within nanocarriers/theoretical mass of drug within
nanocarriers) × 100 (2)
2.4. Structural Analysis
The Rigaku MiniFlex600 x-ray diffractometer (Rigaku Corporation, Tokyo, Japan) was
used for atomic and molecular structural analysis of the samples at a 5−35◦ range and
step size of 0.01◦ (the scanning rate was 2◦/min). XRD patterns were obtained for pure
HT, DFO, P68 and DQA, as well as the P68 + DQA HT and HT + DFO nanocarriers (in
lyophilized form). All XRD analysis was carried out at room temperature.
A PerkinElmer Spectrum 100 FTIR spectrometer (PerkinElmer, Waltham, MA, USA)
was used to analyse the chemical structure of the pure drugs, nanocarriers alone, their
physical mixtures and lyophilised drug-loaded nanocarriers from 650 to 4000 cm−1, at a
resolution of 4 cm−1.
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2.5. Antioxidant Power of the Antioxidant Nanoformulations
The modified ferric iron reducing antioxidant power (FRAP) assay was used to de-
termine the potential antioxidant activity of HT-loaded nanoparticles compared to free
HT at a range of concentrations, as previously described [22,25]. Briefly, FRAP reagent (a
mixture of pH 3.6 acetate buffer, tripyridyl triazine, and iron (III) chloride) and samples of
free and P68+DQA HT were incubated for 30 min at room temperature before being read
at 593 nm. In line with previous reports [25,45,46], trolox was used as the standard and the
antioxidant capacity of the samples was given as the trolox equivalent concentration.
2.6. SH-SY5Y Cell Culture and Cytotoxicity Testing of the Nanoformulations
SH-SY5Y cells were grown in plastic T75 (75 cm2) flasks at 37 ◦C (5% CO2) until
70% confluent. The culture media consisted of pH 7.4 DMEM-Glutamax®, 10% FBS
and 1% antibiotic/antimycotic. Following trypsinisation, SH-SY5Y cells were seeded
(1,000,000 cells/cm2) into 96-well plates ready for the experimental assays to be carried out.
For cytotoxicity evaluation of the drug-loaded nanoformulations, SH-SY5Y cells were
treated with free HT and HT + DFO or the corresponding concentrations of each drug-
loaded nanoformulation for 24, 48 and 72 h. The MTT assay was used to assess cell viability
based on the reduction of the yellow thiazolyl blue tetrazolium bromide salts (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, MTT) to the purple formazan by
mitochondrial dehydrogenases, as previously described [24,25]. Briefly, once confluent
cells were treated with either free or nanoformulated HT at varying concentrations for up
to 72 h. 20 µL of MTT diluted in DPBS (5 mg/mL) was then added to the cells. Following a
4 h incubation at 37 ◦C and aspiration of the wells, 100 µL of DMSO was used to dissolve
any resulting formazan crystals and the plates were incubated for 15 min on a shaker
(75 rpm). The absorbance was then read at 570 nm on a spectrophotometer.
2.7. hCMEC/D3 Cell Culture
An in vitro model of the BBB was created using the hCMEC/D3 cerebral microvascu-
lar endothelial cell line, as previously described [47–52]. hCMEC/D3 cells were grown in
T75 flasks in a 5% CO2 environment at 37 ◦C in Microvascular Endothelial Cell Growth
Medium-2 BulletKitTM (EGM-2 MV) which is supplemented with 5% FBS, 0.04% hydro-
cortisone, 0.4% hFGF-B (human basic fibroblast growth factor), 0.1% VEGF (vascular
endothelial growth factor), 0.1% R3-IGF-1 (human recombinant insulin-like growth factor),
0.1% ascorbic acid and 0.1% GA (gentamicin sulfate-amphotericin). Once sufficiently con-
fluent (~70%), adherent cells were detached from the surface of the flasks using trypsin and
the cells were seeded at 300,000 cells/cm2 into the 3.0 µm pore polycarbonate membrane
inserts of 6- and 96-well Costar Transwell® plates precoated with 1:20 type 1 collagen
from calf skin: DPBS (1 h) and 1:100 fibronectin from bovine plasma: DPBS (1 h). The
hCMEC/D3 cells were exposed to VEGF-free media for 72 h prior to testing to promote
tight junction formation [48,50,52,53].
2.8. Trans-Endothelial Electrical Resistance Assessment
The resistance of the BBB model was assessed using trans-endothelial electrical re-
sistance (TEER) measurements as previously described by Burkhart et al. [54]. TEER
values were read using an epithelial Volt-Ohm meter and sterile Chopstick Electrodes
and expressed as Ω·cm2 (resistance of the tissue (Ω) × membrane area (cm2)). Tight junc-
tions increase the resistance, therefore, high TEER values are desired [51]. TEER values
of hCMEC/D3 cells have been shown to reach 300 Ω·cm2 in the presence of hydrocorti-
sone [49,53,55]). Therefore, before carrying out any of the BBB passage experiments, TEER
values were measured each day post seeding into Transwell® plates, until a resistance of
close to 300 Ω·cm2 was reached.
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2.9. Assessment of Nanocarrier Passage across the hCMEC/D3 BBB Model
The ability of the nanoformulations to pass across the model BBB was assessed using a
transport assay as previously described [56,57]. Phenol red-free HBSS was used to carefully
wash each chamber three times, avoiding disturbance to the hCMEC/D3 monolayer.
In total, 1 and 2.5 mL HBSS was then added to the apical and basolateral chambers
(respectively) and incubated for 10 min at 37 ◦C. The apical chamber was then aspirated and
treated with 1.5 mL nanoformulated or corresponding free HT and HT + DFO treatments
(in HBSS) at a range of concentrations for 1 h at 37 ◦C. Following sampling of the basolateral
chambers, HT content was calculated using UV-Vis spectroscopy at 280 nm as described
above. To assess the stability of the BBB model and potential cytotoxicity of the treatments,
TEER measurements were taken immediately after each transport assay.
2.10. hCMEC/D3 and SH-SY5Y Co-Culture in the Costar Transwell® System
The hCMEC/D3 cells were seeded at 300,000 cells/cm2 into the 3.0 µm pore poly-
carbonate membrane inserts of 96-well Costar Transwell® plates as described above. In
parallel, SH-SY5Y cells were seeded at 1,000,000 cells/cm2 into 96-well plates. Once the
hCMEC/D3 cells reached a membrane potential of at least 300 Ω·cm2 and the SH-SY5Y
cells reached confluence, the hCMEC/D3 cultured Transwell® inserts were place into the
96-well plates containing the confluent SH-SY5Y cells ready for immediate treatment.
2.11. Assessment of the Protective Effects of the Nanocarriers against Rotenone Following Passage
across the BBB Model
SH-SY5Y cells in the basolateral chamber of the Transwell® co-culture system were
treated with 200 µL MEM. hCMEC/D3 cells in the apical chamber were treated with
150 µL of nanoformulated or free HT or HT + DFO treatments (in HBSS) at a range of
concentrations. The cells were then incubated at 37 ◦C for 1 h. The Transwell® inserts
containing the hCMEC/D3 cells were then removed and the SH-SY5Y cells were incubated
for a further 2 h at 37 ◦C. Following incubation, SH-SY5Y cells were treated with 100 µM
rotenone for 24 h at 37 ◦C. The MTT assay was then carried out as described above to assess
the ability of the treatments to protect against reduced cell viability induced by rotenone
after passing the BBB model.
The mitochondrial hydroxyl radical detection assay was conducted to assess the
protective effects of the nanoformulations against rotenone induced oxidative stress in
this co-culture model but using black-walled, clear-bottom 96-well microplates for the
SH-SY5Y cells. This assay was carried out as previously described by Mursaleen et al. [25],
in accordance with the manufacturer’s protocol (ab219931; Abcam, Cambridge, UK). Fol-
lowing treatment with free or nanoformulated HT and HT + DFO and the removal of the
hCMEC/D3 cultured Transwell® inserts (as described above), SH-SY5Y cells were washed
with DPBS and treated for 1 h at 37 ◦C with 100 µL of 6.25X OH580 probe. The cells were
then incubated with 100 µM rotenone for 24 h at 37 ◦C. DPBS was used to wash the cells
before the fluorescence was read on the Fluostar Optima Fluorescence Plate Reader (BMG
LABTECH, Aylesbury, UK).
2.12. Statistical Analysis
The mean of six replicates was calculated for each treatment in all experiments. Data
are expressed as mean ± standard deviation (S.D.). Two-way analysis of variance (ANOVA)
followed by the Tukey’s or Šidák multiple comparisons post hoc test was used to analyse
the FRAP, TEER and BBB passage data. The MTT and mitochondrial hydroxyl assay results
were analysed using one-way ANOVA followed by the Dunnett’s T3 post hoc test (PRISM
software package, Version 8, Graphpad Software Inc., San Diego, CA, USA).
3. Results
Both HT and HT + DFO loaded nanocarriers exhibited high mean encapsulation
efficiency (95% and 97%, respectively) (Table 1). The drug-loaded nanocarriers exhibited a
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significantly higher mean particle size compared to the unloaded blank nanoformulation
(p < 0.0001) (Table 1). The addition of DFO into the formulation increased the mean
encapsulation efficiency of HT by 2%. The mean size of the HT and HT + DFO loaded
nanocarriers were 166 and 146 nm, respectively (Table 1). Although the addition of DFO
to the HT P68 + DQA nanoformulation appeared to lower the particle size, this was not a
significant difference (Table 1). The mean polydispersity indices of the nanoformulations
were < 0.24 which indicates that the majority of the nanocarriers within each formulation
sample were of similar size (Table 1). The mean surface charges of the drug loaded
nanocarriers were moderately positive (7–10 mV) whereas the surface charge of the blank
unloaded nanoformulation was slightly negative (−0.78 mV) (Table 1).
XRD spectra for free and nanoformulated HT and HT + DFO are shown in Figure 1
along with the physical mixture of the components of each nanoformulation and the
individual formulation components (P68 and DQA). A high level of crystallinity is shown
with the HT spectrum, with the main peaks at 8.74◦, 10.2◦, 16.98◦, 25.02◦, 29.98◦, 34.66◦,
38.3◦, 44.9◦, 51.44◦, 51.58◦ (Figure 1(iA,iiA)). As previously reported by Mursaleen et al. [25],
DFO has a large number of peaks indicating crystallinity (Figure 1(iiB)), whereas both P68
and DQA have less peaks within their spectra (Figure 1(iB,C,iiC,D)). Both the P68+DQA
HT and HT + DFO lyophilized formulations present a more amorphous nature, with only
4 clear peaks (8.9, 34.7, 38.3 and 44.6◦) (Figure 1(iE,iiF)). This reduction of peaks was not as
prominent for the physical mixtures (Figure 1(iD,iiE)).
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Figure 1. (i) P68+DQA HT. XRD spectra for (A) HT, ( ) 68, ( ) , ( ) P68, DQA and HT in a phys-
ical mixture (using the same ratio as the nanoformulation), (E) P68+DQA HT (lyophilized nanofor-
mulation). (ii) P68+DQA HT+DFO. XRD spectra for (A) HT, (B) DFO, (C) P68, (D) DQA, (E) P68,
DQA and HT in a physical mixture (using the same ratio as the nanoformulation), (F) P68+DQA
HT+DFO (lyophilized nanoformulation). The P68, DQA, and DFO spectra are as previously reported
by Mursaleen et al. [25]).
Figure 2 shows the FTIR spectrum for the P68 + DQA HT and HT + DFO lyophilized
formulations, the individual components of each formulation and the physical mixture
of these components. The HT FTIR spectrum (Figure 2(iA,iiA)) indicates the presence of
characteristic hydroxyl groups with sharp peaks at 3385, 1447 and 1187 cm−1.
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The strong peak at 1606 cm−1 represents the stretching vibrations of the C=C bonds
within the aromatic ring. The FTIR spectrum for DFO (Figure 2(iiB)) shows peaks represent-
ing stretching vibrations of characteristic bonds for OH (3324, 1472, 1386 cm−1), C=O (2864,
1652, 1536, 974 and 897 cm−1), NH2 (1598 cm−1), and N-H (3115, and 1608 cm−1). The
FTIR spectrum for P68 (Figure 2(iC,iiD)) shows peaks at around 2880, 1060 and 841 cm−1
representing the vibrations of the hydroxyl groups and the stretching vibrations of the
symmetrical C-O and asymmetrical C-O of the ether groups, respectively. The sharp
peak at 1279 cm−1 represents the vibrations of the methylene group. The DQA spectrum
(Figure 2(iC,iiD)) shows the absorption peaks at 3342 and 3264 cm−1 which represent the
two primary amine groups for the asymmetric and symmetric N-H stretches. The sharp
peak at 1605 cm−1 represents the vibration of aromatic C=C bonds. Methyl group stretching
and deformation is represented by the peaks at 2928 and 2847 cm−1. The physical mix-
tures for each formulation (Figure 2(iD,iiE)) show peaks corresponding to each constituent
within the mixture. However, the HT and DFO peaks appear less intense in the mixtures
(Figure 2). The FTIR spectrum for each of the lyophilized formulations are similar to those
of the physical mixtures but in each case the peaks corresponding to the HT and DFO
elements are less intense (Figure 2(iD,iE,iiE,iiF)).
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Figure 3 shows the antioxidant capacity of free and P68 + DQA nanoformulated HT
(10–200 µM), analysed using the FRAP assay. When comparing the different concentrations
of HT (F(6, 70) = 427.5, p < 0.0001) and free vs nanoformulated HT (F(1, 70) = 1029,
p < 0.0001), significant differences were observed. Each P68 + DQA concentration of HT,
except 10 µM, exhibited significantly higher trolox equivalent antioxidant capacity than the
corresponding concentrations of free HT (p < 0.0001) (Figure 3). The percentage increase in
antioxidant capacity of the P68 + DQA HT compared to the free HT preparations were over
100% for most concentrations (20, 40, 80, 100, and 200 µM) but all were over 93% (Figure 3).
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Figure 3. Antioxidant act vity of free and P68 + DQA nanoformulated 1 –200 µM HT measured
by the FRAP assay (mean ± S.D., n = 6). * represe ts signific nc values nanoformulated drug
compared to free drug within the same treatment condition (**** p < 0.0001).
The same concentration ranges of fr e and P68 + DQA HT were then tested on the
SH-SY5Y cell line to evaluate the cytotoxicity of each concentration, using the M T assay.
Ce l viability was maintained at control levels or above fo lowing treatment for 24 h with
10–200 µ free and P68 + DQA HT (F(21, 81.45) = 6.801, p < 0. 01) (Figure 4). No signifi-
cant red cti i ll viability was observed for any concentration of HT (free or f rmulated)
following 48 h treatment (Figure 4B). Although Figure 4B shows a significant reduction
of cell viability compared to control, when treating with 200 µM free HT (p = 0.0135) and
the corresponding blank formulations at 80 µM (p = 0.0338) and 100–200 µM (p < 0.0001),
cell viability was above 80% in all cases (F(21, 57.30) = 6.9155, p < 0.0001). By the 72 h time
point, a significant reduction in cell viability was observed for free HT at 40 µM (p = 0.0141),
free and P68 + DQA formulated HT at 60–200 µM (p < 0.0001), and with the corresponding
blank formulations (p < 0.0005) (Figure 4C). However, no cytotoxicity was observed with
40 µM treatment of free and P68 + DQA formulated HT (F(21, 73.11) = 29.41, p < 0.0001)
(Figure 4C).
The 10 and 20 µM concentrations of free and P68 + DQA HT exhibited no cytotoxicity
at any time point (24, 48 or 72 h) and were therefore used in the subsequent evaluations.
The 50 and 100 µM DFO were used for the combined treatments based on our previous
reports [24,25].
The mean TEER of hCMEC/D3 cell monolayers grown on Transwell® inserts peaked
at 320 Ω·cm2 on day five post seeding and no significant difference in TEER was observed
following any of the free and nanoformulated HT and HT + DFO treatments (Figure 5).
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When comparing the P68 + DQA nanoformulation and free drug treatments of HT
and HT + DFO, significant differences in the percentage of HT were observed following
BBB passage (F(1, 32) = 406.4, p < 0.0001) (Figure 6). All P68 + DQA formulations of HT and
HT + DFO resulted in significantly more HT (between 34.8 and 50.1%) compared to the free
drug treatments (p < 0.0001 in all cases), reaching more than 76% HT following passage
across the hCMEC/D3 monolayer with the P68 + DQA 10 µM treatment (Figure 6).
When assessing the ability of free and P68 + DQA HT and HT + DFO to protect against
rotenone induced cytotoxicity following BBB passage, significant differences were observed
(F(9, 22.26) = 49.87, p < 0.0001) (Figure 7). All free and P68 + DQA HT and HT + DFO pre-
treatments resulted in significantly higher cell viability compared to rotenone treatment
alone (10 µM HT-free: p = 0.0003, P68 + DQA: p = 0.0002, 20 µM HT-free: p = 0.0001,
P68 + DQA: p = 0.0023, 10 µM HT + 50 µM DFO-free: p = 0.0004, P68 + DQA: p < 0.0001
and 20 µM HT + 100 µM DFO-free & P68 + DQA: p < 0.0001), however, only P68 + DQA
20 µM HT and P68 + DQA 20 µM HT + 100 µM DFO maintained cell viability at 80% of
control (Figure 7). The P68 + DQA nanoformulations of both concentrations of combined
HT and DFO resulted in significantly higher cell viability compared to the corresponding
free drug conditions (10 µM HT + 50 µM DFO: 8.7%, p = 0.0125 and 20 µM HT + 100 µM
DFO: 12.3%, p = 0.0006, respectively) (Figure 7).
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Figure 6. Mean percentage of HT in the basolateral compartment of the hCMEC/D3 Transwell®
system following 60 min treatment with free or P68 + DQA HT (10 and 20 µM) and combined HT
and DFO (10 and 20 µM HT + 50 and 100 µM DFO, resp ctively). Percentage HT = ((a sorbance of
the basolateral compartment sample − control)/(absorbance of the treatment- control)) × 100, where
the absorbance was read at 280 nm and the control was MEM. * represents significance values of
nanoformulated drug compared to free drug within the same treatment condition (**** p < 0.0001).
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Antioxidants 2021, 10, 887 12 of 18
Mitochondrial hydroxyl levels were also assessed using the Transwell® model to
evaluate the ability of the free and nanoformulated treatments to protect against rotenone
induced oxidative stress. Significant differences were observed when using the mitochon-
drial hydroxyl assay to assess the ability of free and P68 + DQA HT and HT + DFO to pro-
tect against rotenone induced oxidative stress in the Transwell® model (F(8, 28.41 = 107.9,
p < 0.0001) (Figure 8). Both 10 and 20 µM P68 + DQA HT conditions resulted in significantly
lower levels of hydroxyl compared to the corresponding free drug conditions (p = 0.0298
and p = 0.0003, respectively) (Figure 8). However, the combination of 10 µM HT and 100 µM
DFO in P68 + DQA nanoformulations resulted in the lowest percentage mitochondrial
hydroxyl levels relative to control (1.3%) compared to all the other HT and HT + DFO
treatments (Figure 8).
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cells were grown on the insert and the SH-SY5Y cells were located at the bottom of the basolateral
compartment. Treatments were added to the apical compartment of the Transwell® system and
incubated for 3 h, the SH-SY5Y cells were then incubated with 100 µM rotenone for 24 h. These
results were compared to rotenone treatment alone. Mitochondrial hydroxyl levels are expressed as
the percentage of hydroxyl identified in control cells (SH-SY5Y cells treated with MEM media only,
for 24 h). (mean ± S.D., n = 6). * represents significance values of control or pre-treatment conditions
compared to rotenone treatment alone (**** p < 0.0001, ** p < 0.01). # represents significance values
of nanoformulated drug compared to free drug within the same treatment condition (### p < 0.001,
# p < 0.05).
4. Discussion
There is increasing evidence suggesting that HT is protective in numerous models
of PD [2,11,17–19,58,59]. Yet, the full therapeutic potential of HT as a disease modifying
treatment for PD is unlikely to be reached due to issues such as low bioavailability and
stability, lack of targeted delivery, and limited brain delivery [20]. The aim of this study
was firstly to assess the ability of the P68 + DQA micellar nanocarriers (developed by
Mursaleen et al. [24,25]) to incorporate HT, alone or in combination with DFO, and sec-
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ondly to assess whether these nanoformulations could protect against reduced cell viability
and increased oxidative stress induced by a rotenone model of PD in a hCMEC/D3-SH-
SY5Y Transwell® co-culture system.
HT, alone or combined with DFO, was successfully incorporated into P68 + DQA
nanocarriers with high loading efficiency (Table 1). This is consistent with the encapsulation
efficiencies of these nanocarriers with other antioxidants [24,25]. The HT and HT + DFO
P68 + DQA nanocarriers exhibited consistent particle sizes (polydispersity indices < 0.24),
each below 170 nm (Table 1), suggesting that these formulations should be of dimensions
sufficient to cross the BBB based on previous reports [23,60,61]. The mean surface charges
of the HT and HT + DFO P68 + DQA nanoformulations were similarly neutral (+7.43 and
+9.87 mV, respectively) (Table 1). These relatively neutral surface charges suggest that these
HT P68 + DQA nanocarriers, with and without the combination of DFO, should be able to
access the brain without causing toxicity to the BBB [23,28,30,31,62,63].
XRD studies revealed the crystalline nature of free HT and DFO. This was suppressed
by formulation into P68 + DQA nanocarriers (Figure 1). This amorphous transformation is
of benefit to these formulations due to the known association with increased solubility and
stability [64]. This suggests that these HT and HT + DFO P68 + DQA nanoformulations
would be suitable for oral or nasal delivery as they should remain stable once ingested
or inhaled and would be more easily absorbed into the blood for systemic or neuronal
circulation than free HT and HT + DFO, due to the increased solubility [65]. The decrease
in intensity of the HT and DFO peaks, with minimal shifting, in the FTIR spectra for the
relevant lyophilized formulations compared to the physical mixtures (Figure 2) indicates
the incorporation of each of these drugs into the P68 + DQA nanoformulations, without
any conjugation interactions between the chemical groups [22,66].
The concentration ranges selected for HT (10–200 µM) and tested in the FRAP and
MTT assays were based on and consistent with previous literature [2,67–69]. The FRAP
results show a correlation between increased concentration of HT and increased antioxidant
capacity (Figure 3). Generally, the P68 + DQA HT nanoformulations exhibited significantly
higher antioxidant capacity than the corresponding free HT concentrations (Figure 3).
This is likely due to the improved stability of HT when loaded into the P68 + DQA
nanocarriers as low stability is a possible disadvantage for polyphenols such as HT due to
the extraction process [20]. Ultimately, the 10 and 20 µM concentrations of HT were selected
for further evaluation as these were the highest concentrations of both the free drug and
P68 + DQA nanoformulations that resulted in no observable cytotoxicity in SH-SY5Y cells
after treatment for up to 72 h (Figure 4).
The hCMEC/D3 cell line was used to model the BBB in a Transwell® system based
on previous studies [47–52]. The different free and nanoformulated HT treatments, alone
and in combination with DFO, were tested on this model to assess whether they are likely
to enter the brain in vivo and to evaluate the protective effects of these treatments against
rotenone induced oxidative stress. Importantly, no significant differences in TEER values
were observed following treatment with all concentrations of free and P68 + DQA HT and
HT + DFO (Figure 5), suggesting that none of these treatments are likely to cause toxicity
to the BBB. The results of this study indicate that HT can pass across the BBB to some
extent as supported by previous literature [11,18,19]. However, in every case P68 + DQA
nanoformulation increased the percentage of HT reaching the basolateral compartment of
the Transwell® model by up to 50% (with 10 µM HT) (Figure 6).
Rotenone was used to model PD in this system as it is a pesticide and insecticide
that is commonly used to induce the characteristic features of PD in both in vitro and
in vivo models [70]. It is a strong inhibitor of mitochondrial complex 1 and has been linked
to the higher incidences of PD in agricultural areas [71,72]. Rotenone inhibits electron
transfer from the iron-sulphur clusters in complex I to ubiquinone which blocks oxidative
phosphorylation and limits ATP synthesis [73]. Such incomplete electron transfer also
results in the excessive formation of ROS and together eventually leads to apoptosis of
the affected cells [74–76]. Unlike other neurotoxin models of PD, rotenone models have
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been shown to produce the most PD-like motor symptoms in animals as well as the most
histopathological hallmarks of PD, from iron accumulation and oxidative stress to Lewy
body pathology [77–82].
When using the Transwell® model to evaluate the protective effects of free and
P68 + DQA HT and HT + DFO against rotenone induced cytotoxicity and mitochon-
drial hydroxyl in SH-SY5Y cells following passage across the hCMEC/D3 membrane,
the P68 + DQA nanoformulated treatments were superior in every case (Figures 7 and 8).
This indicates that the P68 + DQA formulations were able to mostly stay intact until
reaching the mitochondria within the SH-SY5Y cells, as it is here where rotenone exerts
its effects as a mitochondrial complex 1 inhibitor [72]. The highest concentrations of the
P68 + DQA combinations of HT and DFO were the most effective of the treatments at
protecting against rotenone induced cytotoxicity and increased mitochondrial hydroxyl,
in both cases maintaining cell viability above 80% and hydroxyl at least in line with con-
trol levels (Figures 7 and 8). However, there was no significant difference between the
20 µM HT and 20 µM HT + 100 µM DFO pre-treatments. This perhaps relates to the
reported iron chelating properties of HT [83], suggesting that there may be little added
value in combining HT and DFO, despite the combination treatments being the most
effective overall.
Taken together, these results suggest that P68 + DQA HT and HT + DFO nanocarriers
have the relevant characteristics to access the brain without producing cytotoxicity and
protect against rotenone induced oxidative stress.
5. Conclusions
This study demonstrates for the first time the incorporation of HT and HT + DFO
into P68 + DQA nanocarriers and successful delivery of these nanocarriers across a BBB
model to protect against PD-related oxidative stress. These results highlight the benefit of
using micellar nanocarriers to improve the passage of HT across biological membranes and
enhance its therapeutic effects. The ability of the P68 + DQA nanocarriers to enhance the
protective effects of HT and HT + DFO against rotenone induced oxidative stress warrants
further investigation in in vivo models as it suggests that these nanocarriers have potential
to become therapeutic agents for PD.
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